Analysis of p53, p16 INK4a, pRb and cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas

Experimental Oncology

Volumn 33, Issue 3, 2011, Pages 150-156

  Bilyk, O O ^a   Pande, N T ^b   Buchynska, L G ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cell cycle proteins; HPV; Ovarian cancer; Prognostic significance

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PROTEIN ANTIBODY; PROTEIN E6; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; ANTIBODIES, MONOCLONAL; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; OVARIAN NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053401444     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Khaskheli M, Baloch S, Baloch AS. Gynecological malignancies: a continuing threat in the developing world. J Gyn Surg 2010; 26: 121-5.
2. Wu QJ, Guo M, Lu ZM, et al. Detection of human papillomavirus-16 in ovarian malignancy. Br J Cancer 2003; 89: 672-5. (Pubitemid 37076171)
3. Salehia F, Dunfield L, Phillipsed KP, et al. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environm Health, Part B: Critical Reviews 2008; 11: 301-21. (Pubitemid 351451267)
4. D'Andrilli G, Giordano A, Bovicelli A. Epithelial ovarian cancer: the role of cell cycle genes in the different histotypes. Open Clin Cancer J 2008; 2: 7-12.
5. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, et al. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D: Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA 1997; 94: 10699-704. (Pubitemid 27430797)
6. Nam EJ, Kim YT. Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18: 1169-82.
7. Barbieri F, Lorenzi P, Ragni N, et al. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 2004; 66: 310-5. (Pubitemid 38822801)
8. Ryan KM, Philips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001; 13: 332-7. (Pubitemid 32429498)
9. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384: 260-5.
10. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systemic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 1611-22.
11. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev 2005; 14: 2550-6. (Pubitemid 41752714)
12. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9. (Pubitemid 29406813)
13. Wu QJ, Guo M, Lu ZM, et al. Detection of human papillomavirus-16 in ovarian malignancy. Br J Cancer 2003; 89: 672-5. (Pubitemid 37076171)
14. Giordano G, D'Adda T, Gnetti L, et al. Role of human papillomavirus in the development of epithelial ovarian neoplasms in Italian women. J Obstet Gynaecol Res 2008; 34: 210-7. (Pubitemid 351537736)
15. Kuscu E, Ozdemir BH, Erkanli S, Haberal A. HPV and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol 2005; 26: 642-5. (Pubitemid 43028060)
16. Anttila M, Syrjanen S, Ji H, et al. Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR. Gynecol Oncol 1999; 72: 337-41. (Pubitemid 29118190)
17. Quirk JT, Kupinski JM, DiCioccio R. Analysis of ovarian tumors for the presence of human papillomavirus DNA. J Obstet Gynaecol Res 2006; 32: 202-5.
18. Voitesek B, Bartek J, Midgley CA, et al. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-44.
19. Turpeinen M, Serpi R, Rahkolin M, Vahakangas K. Comparison of anti-p53 antibodies in immunoblotting. Biochem biophys Res Commun 2002; 293: 850-6. (Pubitemid 34687267)
20. Simmons Kovacs LA, Orlando DA, Haase SB. Transcription network and cyclin/CDKs: The yin and yang of cell cycle oscillators. Cell cycle 2008; 7: 2626-9.
21. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-31. (Pubitemid 33741897)
22. Shiraki M, Odajima T, Ikeda T, et al. Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer. Mod Pathol 2005; 18: 1482-9. (Pubitemid 41509403)
23. Huntsman D, Provencher DM, Mes-Masson AM. Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers 2010; 2: 913-54.
24. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, et al. Immunohistochemical survey of p16INK4a expression in normal human adult and infant tissues. Lab Invest 1999; 79: 1137-43. (Pubitemid 29444545)
25. Buchynska LG, Nesina IP, Yurchenko NP, et al. Expression of p53, p21WAF1/CIP1, p16INK4a and Ki-67 proteins in serous ovarian tumors. Exp Oncol 2007; 29: 49-53. (Pubitemid 46713480)
26. Bali A, O'Brien PM, Edwards LS, et al. Cyclin D1, p53, and p21WAF1/CIP1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 2004; 10: 5168-77. (Pubitemid 39099792)
27. Hashiguchi Y, Tsuda H, Inoue T, et al. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 2004; 35: 165-75. (Pubitemid 38240898)
28. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T. et al. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 2001; 32: 988-96. (Pubitemid 32911323)
29. Atalay F, Taskiran C, Taner MZ, et al. Detection of human papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma. J Obstet Gynaecol Res 2007; 33: 823-8. (Pubitemid 350086515)
30. Ganguly N, Parihar SP. Human papilloma virus E6 and E7 oncoproteins as risk factors fot tumorigenesis. J Biosci 2009; 34: 113-23.
31. Keating JT, Cyiko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4a are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001; 25: 884-91. (Pubitemid 32594981)
32. Monroe M, Wilkinson EJ, Butler SL. Evaluation of p16INK4a immunohistochemical reactivity in endocervical glandular neoplasia. J Lower Genital Tract Disease 2011; 15: 1-5.